HTBX - Heat Biologics is down after announcing publication of COVID-19 vaccine data

Heat Biologics (HTBX) has fallen ~10.7% in the premarket after the company announced that additional preclinical results of its COVID-19 vaccine candidate were published in Frontiers in Immunology, a peer-reviewed journal.Heat Biologics’ COVID-19 vaccine candidate is based on the company's gp96 platform that focuses on inducing T-cells that target the virus-infected cells.The company would not provide quantification but says that new data demonstrated the presence of Spike protein-specific CD8+ and CD4+ T-cell memory responses in the lungs and spleen of immunized animals 30 days after a single vaccination.And 60 days after vaccination, the memory CD8+ T-cell responses were present in the lungs of mice, the statement from the company said, highlighting the importance of vaccination strategies targeting the generation of tissue-resident memory T-cells and their persistence.The initial release of preclinical data of the company’s COVID-19 vaccine candidate sent the stock sharply higher in August.

For further details see:

Heat Biologics is down after announcing publication of COVID-19 vaccine data